Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075167 Target Snapshot

Homeodomain-interacting protein kinase 4 · SINGLE PROTEIN · Homo sapiens

1,343Compounds
205Assays
18Approved Drugs
748.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-12

Protein identity stays anchored to UniProt Q8NE63. Use UniProt Q8NE63 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q8NE63 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-12
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Homeodomain-interacting protein kinase 4 as ChEMBL target CHEMBL1075167, mapped to UniProt Q8NE63. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Homeodomain-interacting protein kinase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
ChEMBL target ID
CHEMBL1075167
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
UniProt accession
Q8NE63
Homeodomain-interacting protein kinase 4
UniProt accession via ChEMBL component mapping As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Homeodomain-interacting protein kinase 4 is the right protein anchor across sources, using UniProt Q8NE63 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHomeodomain-interacting protein kinase 4
UniProt AccessionQ8NE63
Component TypeProtein
Sequence Length616 aa

Homeodomain-interacting protein kinase 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Homeodomain-interacting protein kinase 4, mapped to UniProt Q8NE63. Sequence length is 616 aa.

Mapped IDQ8NE63
Review nameHomeodomain-interacting protein kinase 4
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

18
Approved
7
Phase III
12
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC5044.0
KI618.0
KD86.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1230609 9.29 Kd 0.51 Clinical
CHEMBL1336 8.57 Kd 2.7 Approved
CHEMBL4855209 8.55 IC50 2.8 Preclinical
CHEMBL1336 8.52 IC50 3.0 Approved
CHEMBL4859179 8.48 IC50 3.3 Preclinical
CHEMBL574738 8.41 Kd 3.9 Preclinical
CHEMBL2000335 8.4 Ki 3.981 Preclinical
CHEMBL2004716 8.4 Ki 3.981 Preclinical
CHEMBL411903 8.3 Ki 5.012 Preclinical
CHEMBL4850066 8.29 IC50 5.1 Preclinical
Distribution

pChEMBL Value Distribution

58
5.0
88
5.5
83
6.0
51
6.5
37
7.0
26
7.5
17
8.0
3
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

QUIZARTINIB
CHEMBL576982
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
AFATINIB
CHEMBL1173655
Approved 2013
AFATINIB DIMALEATE
CHEMBL2105712
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
IMATINIB
CHEMBL941
Approved 2001
Assay Landscape

Assay Landscape

205
Total Assays
273
Tested Compounds
2
Assay Types
Binding — 204 assays, 68 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 167 63 6.6
assay format 30 1 6.8
cell-based format 7 4 5.6
Functional — 1 assays, 273 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 273 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine